|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,094 JPY | +1.35% |
|
+4.99% | -4.64% |
| May. 01 | Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation | MT |
| Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
Please refer to the link below for details of the press release:
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab
Contact:
Media
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
(C) 2022 Electronic News Publishing, source
| 1st Jan change | Capi. | |
|---|---|---|
| -4.64% | 54.81B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
CHUGAI PHARMACEUTICAL CO., LTD 
